HAMILTON, ON and BOSTON, Jan. 4, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced significant progress with its FPI-2265 development program, an update on FPI-1434 Phase 1 Cohort 2 data and the production of the first clinical doses at the Company's proprietary manufacturing facility. ย ย ย
Read more at newswire.caFusion Pharmaceuticals Announces Clinical Program and Manufacturing Updates
Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.